Panel amends bill to require Medicaid coverage for fertility preservation in iatrogenic infertility cases

The committee amended and released Assembly Bill 5000, which would require Medicaid to cover fertility preservation services when medically necessary treatments cause iatrogenic infertility. Witnesses — including clinicians, patient advocates and a representative of Ferring Pharmaceuticals — argued the change would align Medicaid beneficiaries with previously expanded coverage under a 2020 law for state‑regulated health plans.

Deb Guston, an attorney representing adoption and assisted‑reproduction clients and professional societies, said AB5000 would correct a coverage gap that leaves Medicaid patients without the same preservation options available to other insured populations. A Ferring Pharmaceuticals representative provided a back‑of‑the‑envelope estimate, stating there might be roughly 21,100 people who would need access statewide, of whom a little over 1,000 might be Medicaid beneficiaries; the witness estimated a preliminary Medicaid cost on the order of about $1.1 million and noted there is a federal matching component that reduces state costs. Survivors and advocacy groups described personal experiences and said utilization since the first law was passed has been low (about 30 percent of eligible patients in their account), lowering projected fiscal impact.

Members asked for more precise fiscal numbers and for written follow‑up from industry and advocates; the committee moved to amend and release the bill and several members recorded abstentions while others voted yes. Multiple professional societies and patient groups filed in favor of the measure for the record.

What’s next: Proponents were asked to provide more detailed fiscal estimates and utilization data to the committee record.